



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Applicant(s) : FINKE, Andreas et al.
Serial No. : 10/774,325
Filed : July 12, 2004
Title : PROCESS OF PRODUCTION OF PROTIEN-COATED MICROPARTICLES
Docket : RDID01062CUS
Art Unit : 1641
Confirm. No. : 8527

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

"Express Mail" Label No. EV696950828US

Date of Deposit: October 6, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Michelle R. Wilson

Signature of person mailing paper or fee

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.56, 1.97 & 1.98

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 CFR §1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56(a). While the information referred to in this Supplemental Information Disclosure Statement may be material pursuant to 37 CFR §1.56(b), the filing of this Supplemental Information Disclosure Statement is not intended to, pursuant to 37 CFR §1.97(h), constitute an admission that any patent, publication, or other information referred to is, or is considered to be, material to the patentability of this invention. No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 & 103, and Applicants reserves the right, pursuant to 37 CFR §1.131 or otherwise, to establish otherwise. Further, pursuant to 37 CFR §1.97(g), the filing of this Statement should not be construed as a statement that a search has been made or that no other material information exists.

The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37

10/11/2005 HDENESS1 00000086 022958 10774325

01 FC:1806

180.00 DA

Serial No. 10/774,325
Docket No. RDID01062CUS

CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by the fee set forth in 37 CFR 1.17 (p).

The Office has waived the requirement pursuant to 37 CFR §1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after June 30, 2003. Therefore, no copies of each cited U.S. patent and each cited U.S. patent application publication are enclosed, but the cited U.S. patents and the cited U.S. patent application publications are listed on PTO/SB/08A.

The Commissioner is authorized to charge \$180.00 to Deposit Account 02-2958.

Respectfully submitted,

ROCHE DIAGNOSTICS OPERATIONS, INC.

Date: 10/6/2005

By Marilyn L. Amick
Marilyn L. Amick
Registration No. 30,444
9115 Hague Road
Indianapolis, IN 46250-0416
Telephone: (317) 521-7561
Facsimile: (317) 521-2883

Serial No. 10/774,325
Docket No. RDID01062CUS

CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by the fee set forth in 37 CFR 1.17 (p).

The Office has waived the requirement pursuant to 37 CFR §1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after June 30, 2003. Therefore, no copies of each cited U.S. patent and each cited U.S. patent application publication are enclosed, but the cited U.S. patents and the cited U.S. patent application publications are listed on PTO/SB/08A.

The Commissioner is authorized to charge \$180.00 to Deposit Account 02-2958.

Respectfully submitted,

ROCHE DIAGNOSTICS OPERATIONS, INC.

Date: 10/6/2005

By Marilyn L. Annick
Marilyn L. Annick
Registration No. 30,444
9115 Hague Road
Indianapolis, IN 46250-0416
Telephone: (317) 521-7561
Facsimile: (317) 521-2883

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/744,325
				Filing Date	July 12, 2004
				First Named Inventor	Andreas FINKE
				Group Art Unit	1641
				Examiner Name	Christine E. Foster
				Attorney Docket Number	RDID01062CUS
Sheet	1	of	1		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.